Agenda

Day 1 - Monday, April 28, 2014

7:00
Registration And Continental Breakfast
8:15
Co-Chairs’ Opening Remarks On The 30th Anniversary Of The Drug Price Competition And Patent Term Restoration Act: Understanding Hatch-Waxman’s Transformative Impact On The Pharmaceutical Industry
9:00
Assessing Pharmaceutical Patent Sustainability And Vulnerability: Strategies And Considerations For Brand Names And Generics In Anticipating, Identifying And Determining Which Patents Will Be Ripe For Challenges Of Invalidity And Non-Infringement
10:00
Morning Coffee Break
10:15
Use Of IPR And Other PTO Proceedings In A Paragraph IV Challenge: Strategies For Brand Names And Generics In Navigating PTO Proceedings In ANDA Litigation
11:15
The Gauntlet Rethrown: The Paragraph IV Certification And Notice Letter
12:15
Networking Luncheon
1:30
Of Prior Art And Double Patenting: Exploring The Dichotomy Between The Federal Circuit And PTO On Obvious Findings And The Potential Impact Of The Goodlatte Bill On Double-Patenting Type Obviousness
2:30
Afternoon Refreshment Break
2:45
Let The Games Begin: Advanced Strategies For Drafting And Perfecting Pleadings And Effectively Using Dispositive Motions In Paragraph IV Disputes
3:45
Working With Local Counsel And Within Local Rules: Magistrate And Local Counsel Roundtable
4:45
A View From The Bench
6:00
Conference Adjourns to Day Two

Day 2 - Tuesday, April 29, 2014

7:30
Co-Chair’s Opening Remarks and Recap of Day 1
8:15
Claim Construction And Markman Hearings: Standards, Jurisprudential Splits And Strategies For Paragraph IV Litigation
9:15
FTC Keynote: Reverse Payment Settlements And Other Antitrust Concerns Impacting Paragraph IV Litigation In The Wake Of Activis
10:00
Morning Coffee Break
10:15
Perils Of The Safe Harbor: Understanding How The Resetting Of The Boundaries Of 271 (e)(1) In The Aftermath Of Classen And Momenta Is Impacting Paragraph IV Litigation Strategies
11:15
In The Limelight: Strategies And Theories Of Inducement, Contributory And Divided Infringement In Paragraph IV Litigation Concerning Method Of Treatment Patents
12:15
Networking Luncheon
1:30
Assessing GDUFA Implementation And Additional Regulatory Developments Of FDA Which Impact Paragraph IV Litigation
2:30
Looking Beyond 180 Days: New Exclusivity Challenges For Brand Names And Generics And Related Implications For Paragraph IV Challenges
3:15
Afternoon Refreshment Break
3:30
A Pros And Cons Analysis Of Launching At Risk And Survey Of New Developments In Seeking Injunctive Relief And Damages
4:45
Ethical Considerations For Paragraph IV Matters Before The PTO And District Courts: Inequitable Conduct And More
5:45
Conference Ends

Day 1 - Monday, April 28, 2014

7:00
Registration And Continental Breakfast
8:15
Co-Chairs’ Opening Remarks On The 30th Anniversary Of The Drug Price Competition And Patent Term Restoration Act: Understanding Hatch-Waxman’s Transformative Impact On The Pharmaceutical Industry
9:00
Assessing Pharmaceutical Patent Sustainability And Vulnerability: Strategies And Considerations For Brand Names And Generics In Anticipating, Identifying And Determining Which Patents Will Be Ripe For Challenges Of Invalidity And Non-Infringement
10:00
Morning Coffee Break
10:15
Use Of IPR And Other PTO Proceedings In A Paragraph IV Challenge: Strategies For Brand Names And Generics In Navigating PTO Proceedings In ANDA Litigation
11:15
The Gauntlet Rethrown: The Paragraph IV Certification And Notice Letter
12:15
Networking Luncheon
1:30
Of Prior Art And Double Patenting: Exploring The Dichotomy Between The Federal Circuit And PTO On Obvious Findings And The Potential Impact Of The Goodlatte Bill On Double-Patenting Type Obviousness
2:30
Afternoon Refreshment Break
2:45
Let The Games Begin: Advanced Strategies For Drafting And Perfecting Pleadings And Effectively Using Dispositive Motions In Paragraph IV Disputes
3:45
Working With Local Counsel And Within Local Rules: Magistrate And Local Counsel Roundtable
4:45
A View From The Bench
6:00
Conference Adjourns to Day Two

Day 2 - Tuesday, April 29, 2014

7:30
Co-Chair’s Opening Remarks and Recap of Day 1
8:15
Claim Construction And Markman Hearings: Standards, Jurisprudential Splits And Strategies For Paragraph IV Litigation
9:15
FTC Keynote: Reverse Payment Settlements And Other Antitrust Concerns Impacting Paragraph IV Litigation In The Wake Of Activis
10:00
Morning Coffee Break
10:15
Perils Of The Safe Harbor: Understanding How The Resetting Of The Boundaries Of 271 (e)(1) In The Aftermath Of Classen And Momenta Is Impacting Paragraph IV Litigation Strategies
11:15
In The Limelight: Strategies And Theories Of Inducement, Contributory And Divided Infringement In Paragraph IV Litigation Concerning Method Of Treatment Patents
12:15
Networking Luncheon
1:30
Assessing GDUFA Implementation And Additional Regulatory Developments Of FDA Which Impact Paragraph IV Litigation
2:30
Looking Beyond 180 Days: New Exclusivity Challenges For Brand Names And Generics And Related Implications For Paragraph IV Challenges
3:15
Afternoon Refreshment Break
3:30
A Pros And Cons Analysis Of Launching At Risk And Survey Of New Developments In Seeking Injunctive Relief And Damages
4:45
Ethical Considerations For Paragraph IV Matters Before The PTO And District Courts: Inequitable Conduct And More
5:45
Conference Ends